General MedicationsORALStandard
TALZENNA
TALAZOPARIB TOSYLATE
Standard Dose
EQ 1MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview TALZENNA is listed in Drugs@FDA under application 217439 (NDA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient TALAZOPARIB TOSYLATE Form and strength CAPSULE;ORAL - EQ 1MG BASE Sponsor PFIZER Submission history Latest submission status date: 2025-06-12 00:00:00.
Structured Monograph
Clinical summary
Approval overview TALZENNA is listed in Drugs@FDA under application 217439 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient TALAZOPARIB TOSYLATE Form and strength CAPSULE;ORAL - EQ 1MG BASE Sponsor PFIZER Submission history Latest submission status date: 2025-06-12 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.